Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
BRAZILIAN SOC UROL
Autores
SASSE, Andre Deeke
REIS, Rodolfo Borges dos
NOGUEIRA, Lucas Mendes
MALUF, Fernando Cotait
HERCHENHORN, Daniel
SMALETZ, Oren
LIMA, Volney Soares
SCHUTZ, Fabio
WIERMANN, Evanius Garcia
Citação
INTERNATIONAL BRAZ J UROL, v.45, n.3, p.449-458, 2019
Resumo
Prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second only to non-melanoma skin cancers. The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach. The first Brazilian Consensus on the Treatment of Advanced Prostate Cancer was published in 2017, with the goal of reducing the heterogeneity of therapeutic conduct in Brazilian patients with metastatic prostate cancer. We acknowledge that in Brazil the incorporation of differ-ent technologies is a big challenge, especially in the Sistema Unico de Saude (SUS), which allows for the disparity in the options available to patients treated in different institutions. In order to update the recommendations and to make them objective and easily accessible, once more a panel of specialists was formed in order to discuss and elaborate a new Brazilian Consensus on Advanced Prostate Cancer. This Consensus was written through a joint initiative of the Brazilian Society of Clini-cal Oncology (SBOC) and the Brazilian Society of Urology (SBU) to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.
Palavras-chave
Prostatic Neoplasms, Therapeutics, Consensus
Referências
- Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008
- Chi BH, 2018, YONSEI MED J, V59, P389, DOI 10.3349/ymj.2018.59.3.389
- Dalesio O, 2000, LANCET, V355, P1491
- De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
- de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
- Fitzmaurice C, 2018, JAMA ONCOL, V4, P1553, DOI 10.1001/jamaoncol.2018.2706
- Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
- Gillatt D, 2006, J CANCER RES CLIN, V132, pS17, DOI 10.1007/s00432-006-0133-5
- Hershman DL, 2016, JAMA ONCOL, V2, P453, DOI 10.1001/jamaoncol.2015.4655
- Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232
- Hussain M, 2013, NEW ENGL J MED, V368, P1314, DOI 10.1056/NEJMoa1212299
- INCA. Instituto Nacional do Cancer, 2018, EST 2018 INC CANC BR
- James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900
- James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5
- Kolinsky M, 2016, EUR UROL, V69, P841, DOI 10.1016/j.eururo.2015.10.052
- Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657
- Loblaw DA, 2012, J CLIN ONCOL, V30, P3136, DOI 10.1200/JCO.2012.42.0489
- Metcalfe MJ, 2017, UROL ONCOL-SEMIN ORI, V35, P125, DOI 10.1016/j.urolonc.2017.01.001
- Nishiyama T., 2014, UROL ONCOL, V32
- Nishiyama T, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.03.007
- Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
- Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7
- Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
- Sasse AD, 2017, INT BRAZ J UROL, V43, P407, DOI [10.1590/S1677-5538.IBJU.2016.0490, 10.1590/s1677-5538.ibju.2016.0490]
- Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
- Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
- Schmid S, 2015, ANN ONCOL, V26, P2221, DOI 10.1093/annonc/mdv326
- Sun MX, 2016, JAMA ONCOL, V2, P500, DOI 10.1001/jamaoncol.2015.4917
- Vale CL, 2016, LANCET ONCOL, V17, pE46
- Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470-2045(15)00489-1